Advisors Asset Management Inc. Has $3.47 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Advisors Asset Management Inc. cut its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 6.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 166,047 shares of the biopharmaceutical company’s stock after selling 11,286 shares during the period. Advisors Asset Management Inc. owned 0.14% of Catalyst Pharmaceuticals worth $3,465,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of CPRX. Steward Partners Investment Advisory LLC acquired a new stake in Catalyst Pharmaceuticals during the fourth quarter worth approximately $27,000. Farther Finance Advisors LLC increased its holdings in shares of Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 1,495 shares during the period. Larson Financial Group LLC increased its holdings in shares of Catalyst Pharmaceuticals by 27,218.2% during the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 2,994 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of Catalyst Pharmaceuticals during the fourth quarter worth approximately $65,000. Finally, KBC Group NV increased its holdings in shares of Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 1,542 shares during the period. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CPRX has been the topic of several recent research reports. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. Stephens reaffirmed an “overweight” rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Robert W. Baird lifted their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, March 3rd. Bank of America reissued a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Finally, HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $32.50.

Catalyst Pharmaceuticals Stock Performance

NASDAQ CPRX opened at $23.16 on Friday. The firm’s fifty day moving average price is $22.34 and its two-hundred day moving average price is $21.58. The stock has a market cap of $2.81 billion, a PE ratio of 19.63, a PEG ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.47 and a fifty-two week high of $24.64.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the sale, the insider now owns 68,873 shares of the company’s stock, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the transaction, the insider now owns 188,564 shares in the company, valued at approximately $4,333,200.72. This trade represents a 25.04 % decrease in their position. The disclosure for this sale can be found here. Insiders own 11.00% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.